This segment focuses on the development and commercialization of novel immunotherapies and targeted oncology treatments. Key research and development activities include preclinical studies and clinical trials for drug candidates like Cosibelimab, a PD-L1 inhibitor, and CK-302, a GITR agonist. The segment leverages technologies such as monoclonal antibody engineering and small molecule design to create targeted therapies. Therapeutic areas covered include various solid tumor cancers, with a focus on improving patient outcomes through innovative treatment approaches. Market positioning involves competing with established pharmaceutical companies in the oncology space, with a competitive advantage in novel mechanisms of action and targeted delivery. Future opportunities include expanding the pipeline with new drug candidates and exploring combination therapies. Regulatory and clinical aspects involve navigating the FDA approval process and conducting rigorous clinical trials to demonstrate safety and efficacy. Collaborations with other companies, such as GC Cell, are crucial for advancing research and development efforts.